• 26 MAY 2020
    • 0

    PharmaCyte Biotech Announces Final Major Study for IND Submission Has Begun

    LAGUNA HILLS, CA, May 26, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the final major study required by the U.S. Food and Drug Administration (FDA) for the submission of PharmaCyte’s Investigational

    Read more →
    • 11 MAY 2020
    • 0

    PharmaCyte Biotech Conducting Final Audit of Manufacturing Facility after Batch Records Deemed cGMP Compliant

    LAGUNA HILLS, CA, May 11 , 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that cGMP Validation, the company’s GMP consultant, is conducting its final audit of the manufacturing facility in Thailand where

    Read more →
    • 06 MAY 2020
    • 0

    PharmaCyte Biotech Receives Medical Devices Registration and Submits Pre-EUA Application to the FDA for COVID-19 Diagnostic

    LAGUNA HILLS, CA May 6, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received Medical Devices Establishment Registration with the FDA’s Center for Devices and Radiological Health (CDRH). The CDRH

    Read more →
    • 04 MAY 2020
    • 0

    PharmaCyte Biotech Completes Medical Manual for IND Filing

    LAGUNA HILLS, CA May 4, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has completed a medical manual that is pivotal to the completion of its Investigational New Drug application (IND)

    Read more →
    • 27 APR 2020
    • 0

    PharmaCyte Biotech Successfully Completes Pyrogenicity Testing

    LAGUNA HILLS, CA, April 27, 2019 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the crucial pyrogenicity testing that is required by the U.S. Food and Drug Administration (FDA)

    Read more →
    • 08 APR 2020
    • 0

    PharmaCyte Biotech Enters into License Agreement for COVID-19 Diagnostic Kits

    LAGUNA HILLS, CA April 8, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it entered into a License Agreement (Agreement) with Hai Kang Life Corporation Limited, a corporation organized under the laws

    Read more →
    • 12 MAR 2020
    • 0

    PharmaCyte Biotech Addresses Submission of IND and Recent FDA-Required Testing

    LAGUNA HILLS, CA March 12, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the latest in its series of Q&A articles that are conducted with some of the key management members of PharmaCyte’s

    Read more →
    • 12 FEB 2020
    • 0

    PharmaCyte Biotech Receives Certificates of Analysis and Batch Records for its Clinical Trial Product in Pancreatic Cancer

    LAGUNA HILLS, CA February 12, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the Certificates of Analysis and the records from both batches of its clinical trial product manufactured

    Read more →
    • 22 JAN 2020
    • 0

    PharmaCyte Biotech Successfully Completes All Release Tests on Clinical Trial Product

      LAGUNA HILLS, CA January 22, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured clinical trial product have undergone and passed all 10 of the necessary

    Read more →
    • 23 DEC 2019
    • 0

    PharmaCyte Biotech Passing All Completed Tests on Clinical Trial Product

    LAGUNA HILLS, CA December 23, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured clinical trial product have now passed 7 of the 10 completed “release tests”

    Read more →